<DOC>
	<DOCNO>NCT02790645</DOCNO>
	<brief_summary>Diabetes mellitus chronic disease high socio-health relevance clinical economic implication ( risk complication , disability ... ) ( healthcare cost ) . Strict glycemic control intensive treatment support show long-term patient type 1 diabetes mellitus ( DM1 ) improve health . The intensive insulin therapy involve administration insulin 3 injection per day ( MDI ) , continuous subcutaneous insulin infusion ( CSII ) . New technology apply treatment DM1 , telemedicine , could bring benefit patient . The available scientific evidence date show telemedicine system beneficial neutral effect glycemic control , express term HbA1c patient type 1 diabetes treat MDI CSII . They also show worsen quality life reduce cost associate care subject . However , study publish date generally short follow-up , small sample size , evaluate biological parameter glycemic variability , inflammatory marker marker oxidative stress well psychological assessment include depression , anxiety , Diabetes-related distress fear hypoglycemia . It design randomize crossover 18 month order study effect telemedicine program group subject DM1 CSII clinical variable metabolic control variable , include parameter glycemic variability , marker inflammation oxidative stress , psychological variable quality life , associate cost .</brief_summary>
	<brief_title>Telemedicine Program Type 1 Diabetes CSII</brief_title>
	<detailed_description>Randomized crossover clinical trial impact telemedicine program ( Emminens Conecta® System , Roche Diagnostics SL ) vs. conventional medical follow-face 18 month care patient DM1 intensive treatment CSII ( Accu-Chek Spirit® , Roche SL ) . Two group : one group interactive clinical monitoring telemedicine platform ( TM ) conventional medical follow-up group ( SMC ) 6 month . Being crossover trial , group pass condition ( TM SMC ) 6 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Type 1 diabetes 2 year development C plasma level &lt; 0.5 ng / ml , ISCI treat &gt; 6 month peptide . Age 16 65 year ( inclusive ) . HbA1c &lt; 10 % . Absence concomitant drug therapy could affect blood glucose level . Absence chronic renal failure , abnormal liver function test , thyroid disease active ( except properly replace hypothyroidism ) . Absence acute decompensation Ketotic baseline . type 2 diabetes . type 1 diabetes treat multiple daily insulin injection . Women pregnant planning pregnancy . severe macrovascular microvascular complication disable psychological disorder . No collaboration ( sign inform consent ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Health technology</keyword>
	<keyword>Continuous subcutaneous insulin infusion</keyword>
	<keyword>Telemedicine</keyword>
	<keyword>Glycemic variability</keyword>
	<keyword>Inflammatory marker ,</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Depression</keyword>
	<keyword>Quality life</keyword>
	<keyword>Cost-effectiveness</keyword>
</DOC>